Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jing yi Shao, Master
Dongzhimen Hospital of Beijing University of Chinese Medicine
Study Chair - Ke Xu, Master
Dongzhimen Hospital of Beijing University of Chinese Medicine
Principal Investigator - Qin yang Liu, Bachelor
Dongzhimen Hospital of Beijing University of Chinese Medicine
Study Chair - Xi yu Li, Bachelor
Dongzhimen Hospital of Beijing University of Chinese Medicine
Study Chair - Yun Shi
Dongzhimen Hospital of Beijing University of Chinese Medicine
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Dongzhimen Hospital, Beijing University of Chinese Medicine
Beijing, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Jul 2023
- Primary completion
- 20 Jul 2024
- Completion
- 20 Jul 2024
- Last update posted
- 5 Dec 2024
- Registered enrollment
- 46
- Registry id
- NCT06102655
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.